Aims of conditioning

Experimental Hematology

Volumn 31, Issue 10, 2003, Pages 844-854

  Vriesendorp, Huib M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL MODEL; ATOMIC WARFARE; CHEMOTHERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HISTOCOMPATIBILITY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; LYMPHOCYTE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RADIATION ACCIDENT; REVIEW; WHOLE BODY RADIATION;

ANIMALIA;

EID: 0141596018     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00229-7     Document Type: Review

References (92)

1. Quastler H. Studies on roentgen death in mice I. Survival time and dosage . Am J Roentgenol. 45:1945;449-456.
2. Solomon F.C., Marston R.Q. The medical implications of nuclear war. 1986;National Academic Press, Washington DC.
3. Jammet H., Mathé G., Pendic B., et al. Etude de six cas d'irradiation totale aigue accidentelle. Rev Franc Etudes Clin Biol. 4:1959;210-225.
4. Mathé G., Schwarzenberg L. Bone marrow transplantation in France, 1958-1973. Transplant Proc. 6:1974;335-340.
5. Thomas E.D., Storb R., Clift R.A. Bone-marrow transplantation I and II. N Engl J Med. 292:1975;832-843. 895-902.
6. van Bekkum D.W., Löwenberg B. Bone Marrow Transplantation. Biological Mechanisms and Clinical Practice. 1985;Marcel Dekker, New York.
7. Broun E., Nichols C., Kneebone P., et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 117:1992;124-128.
8. Storb R. Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow. Exp Hematol. 31:2003;1-10.
9. Kobbe G., Schneider P., Aivado M., et al. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Exp Hematol. 30:2002;1346-1353.
10. Badros A., Barlogie B., Siegel E., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol. 20:2002;4268-4276.
11. Feinstein L.C., Sandmaier B.M., Hegenbart U., et al. Non-myeloablative allografting from human leucocyte antigen identical sibling donors for treatment of acute leukemia in first remission. Br J Hematol. 120:2003;281-290.
12. Djulbegovic B., Seidenfeld J., Bonell C., Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematological malignancies: A systematic review. Cancer Control: Journal of the Moffitt Cancer Center. 10:2003;17-42.
13. Jacobson L.O., Marks E.K., Robson M.J., Gaston E.O., Zirkle R.E. Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med. 34:1949;1538-1543.
14. van Bekkum D.W., de Vries M.J. Radiation chimaeras. 1967;Logos Press/Academic Press, London.
15. Vriesendorp H.M., van Bekkum D.W. Susceptibility to total body irradiation. Broerse J.J., MacVitti T. Response to Total Body Irradiation in Different Species. 1984;43-53 Martinus Nijhoff, Amsterdam.
16. van Bekkum D.W. Use and abuse of hemopoietic cell grafts in immune deficiency disease. Transplant Rev. 9:1972;3-53.
17. van Bekkum D.W. Graft-vs-host disease. van Bekkum D.W., Lowenberg B. Bone Marrow Transplantation. Biological Mechanisms and Clinical Practice. 1985;147-212 Marcel Dekker, New York.
18. Vriesendorp H.M., Klapwijk W.M., Visser T.P., Zurcher C., van Bekkum D.W. Alternatives to donor matching for control of graft-vs-host disease. Immunogenetics. 15:1982;79-94.
19. Atkinson K., Shulman H.M., Deeg H.J., et al. Acute and chronic graft-vs-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Am J Pathol. 108:1982;196-204.
20. Wagenmaker G., Heidt P.J., Merchav S., van Bekkum D.W. Abrogation of histocompatibility barriers to bone marrow transplantation in rhesus monkeys. Baum J.S., Ledney G.D., Thierfelder S. Experimental Hematology Today 1982. 1982;111-120 Karger, Basel.
21. Vriesendorp H.M., Klapwijk W.M., Heidt P.J., Hogeweg B., Zurcher C., van Bekkum D.W. Factors controlling the engraftment of transplanted dog bone marrow cells. Tissue Antigens. 20:1982;63-80.
22. Gorer P.A., Boyse E.A. Some reactions observed with transplanted reticulo-endothelial cells in mice. Albert F., Lejeune-Ledant G. Biological Problems of Grafting. 1959;193-204 Blackwell, Oxford.
23. Huss H., Deeg H.J., Goolen T., et al. Effect of mixed chimerism on graft-vs-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant. 18:1990;97-104.
24. Ford C.E. Traffic of lymphoid cells in the body. Wolstenhome G.E.W., Porter R. The Thymus: Experimental and Clinical Studies. 1966;131-160 Little & Brown, Boston.
25. Stewart F.M., Crittenden R.B., Lowry P.A., Pearson-White S., Quesenberry P.J. Long term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 81:1993;2566-2571.
26. Vriesendorp H.M. Radiobiological speculations on therapeutic total body irradiation. Crit Rev Onc/Hem. 10:1990;211-224.
27. Lord B.I., Hendry J.H. The distribution of hematopoietic colony forming units in the mouse femur and its modifications by x-rays. Br J Radiol. 45:1972;110-116.
28. Tavassoli M. Structure and function of sinusoidal endothelium of bone marrow. Prog Clin Biol Res. 59B:1981;249-256.
29. Tavassoli M., Aizano S. Homing receptors for hemopoietic cells are lectins with galactosyl and mannosyl specificities. Trans Assoc Am Physicians. 100:1987;294-299.
30. Tavassoli M., Minguell J.J. Homing of hematopoietic progenitor cells to the marrow. Proc Soc Exp Biol Med. 196:1991;367-373.
31. Hardy C.C., Matsuoha T., Tavassoli M. Distribution of homing protein on hemopoietic stromal and progenitor cells. Exp Hematol. 19:1991;968-972.
32. van Buul J.D., Voermans C., van der Berg V., et al. Migration of human hematopoietic progenitor cells across bone marrow endothelium is regulated by vascular endothelial cadherin. J Immunol. 168:2002;588-596.
33. Vriesendorp H.M., Lowenberg B., Visser T.P., Knaan S., van Bekkum D.W. The influence of genetic resistance and silica particles on survival after bone marrow transplantation. Transplant Proc. 8:1976;483-489.
34. Vriesendorp H.M., van Bekkum D.W. Role of total body irradiation in conditioning for bone marrow transplantation. Thierfelder S., Rodt H., Kolb H. Immunobiology of Bone Marrow Transplantation. 1980;349-364 Springer Verlag, Heidelberg.
35. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts I. Graft rejection by irradiated responder mice . J Exp Med. 134:1971;83-90.
36. Konno M., Hardy C., Tavassoli M. Murine spleen culture: homing of hemopoietic progenitor cells to spleen is not mediated by a similar mechanism to that in marrow. Exp Hematol. 18:1990;65-85.
37. Vriesendorp H.M., Wagemaker G., van Bekkum D.W. Engraftment of allogeneic bone marrow. Transplant Proc. 13:1981;643-648.
38. Vriesendorp H.M., Klapwijk W.M., van Kessel A.C.M., Zurcher C., van Bekkum D.W. Lasting engraftment of histoincompatible dog bone marrow cells. Transplantation. 31:1981;347-352.
39. Vriesendorp H.M., Bijnen A.B., Westbroek D.L., van Bekkum D.W. Genetics and transplantation immunology of the DLA complex. Transplant Proc. 9:1977;293-296.
40. Barsoukov A.A., Moore P.F., Storb R., Santos E.D., Sandmaier B.C. The use of an anti TCRαβ monoclonal antibody to control host-vs-graft reactions in canine marrow allograft recipients conditioned with low dose irradiation. Transplantation. 67:1999;1329-1335.
41. van Bekkum D.W., Vos O. Immunological aspects of homo- and heterologous bone marrow transplantation in irradiated animals. J Cell Comp Physiol. 50:1957;139-156.
42. Loutit J.F., Micklem H.S. Active and passive immunity to transplantation of foreign bone marrow in lethally irradiated mice. Br J Exp Pathol. 42:1961;577-586.
43. Vriesendorp H.M., Bijnen A.B., van Kessel A.C.M., Obertop H., Westbroek D.L. Minor histocompatibility systems in dogs. Baum S.J., Ledney G.D. Experimental Hematology Today 1978. 1978;109-119 SpringerVerlag, New York.
44. Wekerle T., Sayegh M.H., Hill J., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 187:1988;2037-2044.
45. Ito H., Kurtz J., Shaffer J., Sykes M. CD4 T cell mediated alloresistance to fully MHC mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol. 161:2001;2970-2981.
46. + cells. Am J Transplant. 4:2001;339-358.
47. + T cell tolerance and linked suppression. J Immunol. 163:1999;4805-4810.
48. Taylor P.A., Lees C.J., Waldmann H., Noelle R.J., Blazar B.R. Requirements for the promotion of allogeneic engraftment by anti-CD154 [anti-CD40L] monclonal antibody under non-myeloablative conditions. Blood. 98:2001;467-474.
49. Vriesendorp H.M. Engraftment of hemopoietic cells. van Bekkum D.W., Lowenberg B. Bone Marrow Transplantation. Biological Mechanisms and Clinical Practice. 1985;73-145 Marcel Dekker Inc. New York.
50. Landsteiner K., Levine P. Further observations on individual differences of human blood. Proc Soc Exp Biol [NY]. 24:1927;941-943.
51. Owen R.D. Immunogenetic consequences of vascular anastomoses between bovine twins. Science. 102:1945;400-402.
52. Stormont C., Weir W.R., Lane L.L. Erythrocyte mosaicism in a pair of sheep twins. Science. 118:1953;695-697.
53. Benirschke K., Anderson J.M., Brownkill L.E. Marrow chimerisms in marmosets. Science. 138:1963;513-515.
54. Dunsford I., Bowley C., Hutchinson A.M., Thompson J.S., Sanger R., Race R.R. A human blood group chimera. Br Med J. 2:1953;81-83.
55. Stone W.H., Cragle R.G., Swanson E.W., Brown D.G. Skin allografts: Delayed rejection between pairs of cattle twins showing erythrocyte chimerism. Science. 148:1965;1335-1339.
56. Nayman J., Data S.P., de Boer W.G.R.M. Renal transplantation in cattle twins. Nature. 215:1967;741-743.
57. Main J.M., Prehn R.T. Fate of skin homografts in X-irradiated mice treated with homologous marrow. J Natl Cancer Inst. 15:1957;1023-1026.
58. Von Scheel J., Kolb H.J., Duswald K.H., et al. Kidney transplantation following treatment with cyclophosphamide and bone marrow grafting. Transplant Proc. 3:1971;708-712.
59. Parkman R., Monir D., Umansky I., et al. Graft vs host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med. 290:1974;359-363.
60. Graw R.G., Buckner C.D., Whang-Peng J., et al. Complications of bone-marrow transplantation. Graft-vs-host disease resulting from chronic-myelogenous-leukemia leucocyte transfusions. Lancet. 2:1970;338-342.
61. UCLA Bone Marrow Transplant Team. Prevention of graft rejection following bone marrow transplantation. Blood. 57:1981;9-14.
62. Ramsay N.K.C., Kim T.H., Nesbit M.E., et al. Total lymphoid irradiation and cyclophosphamide as immunosuppresion for human bone marrow transplantation in severe aplastic anemia. Blood. 55:1980;344-352.
63. Storb R., Etzioni R., Anasetti C., et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplantation in patients with aplastic anemia. Blood. 84:1994;941-949.
64. Devergie A., Gluckman E. Bone marrow transplantation in severe aplastic anemia following cytoxan and thoracoabdominal irradiation. Exp Hematol. (suppl 10):1982;17-18.
65. van Bekkum D.W. Stem cell transplantation in experimental models of autoimmunity. J Clin Immunol. 20:2000;10-16.
66. van Bekkum D.W. Effectiveness and risks of total body irradiation for conditioning in the treatment of autoimmune disease with autologous bone marrow transplantation. Rheumatology. 38:1999;757-761.
67. Lee M.Y., Oh E.S., Min C.K., et al. Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation. Bone Marrow Transplant. 28:2001;63-66.
68. Nelson J.L., Torrez R., Louie F.M., Choe O.S., Storb R., Sullivan K.M. Pre-existing autoimmune disease in patients with long term survival after allogeneic bone marrow transplantation. J Rheumatol. (suppl 48):1997;23-29.
69. Lopez-Cubero S.O., Sullivan K.M., McDonald G.B. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology. 114:1998;433-440.
70. Weiden P.L., Storb R., Graham T.C., Sale G.E., Thomas E.D. Resistance to DLA-nonidentical marrow grafts in lethally irradiated dogs. Transplant Proc. 9:1977;285-288.
71. Deeg H.J., Storb R., Prentice T.E., et al. Increased cancer risks in canine irradiation chimeras. Blood. 55:1980;233-239.
72. Broerse J.J., Bartstra R.W., van Bekkum D.W., et al. The carcinogenic risk of high dose total body irradiation in non-human primates. Radiother Oncol. 54:2000;247-253.
73. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. N Engl J Med. 336:1997;897-904.
74. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 87:1996;386-392.
75. Puck T.T., Marcus P.I. Action of x-rays on mammalian cells. J Exp Med. 103:1956;653-666.
76. Skipper H.E., Schabel F.M., Wilcox W.S. Experimental evaluation of potential anti-cancer agents XII. On the criteria and kinetics associated with 'curability' of experimental leukemia . Cancer Chemother Rep. 35:1964;1-12.
77. Hagenbeek A., Martens A.C. High dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML model. Eur J Cancer Clin Oncol. 18:1982;763-769.
78. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-vs-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 300:1979;1068-1074.
79. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-vs-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. European Group for blood and marrow transplantation. Working Party Chronic Leukemia. Blood. 87:1996;4011-4013.
80. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal cell cancer after non myeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med. 343:2000;802-803.
81. Feinstein L., Sandmaier B., Maloney D., et al. Non myeloablative hematopoietic cell transplantation. Replacing high dose cytotoxic therapy by the graft-vs-tumor effect. Ann NY Acad Sci. 938:2001;328-337.
82. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. Blood. 49:1977;511-520.
83. Thomas E.D., Buckner C.D., Clift R.A., et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 301:1979;597-603.
84. Socie G., Clift R.A., Blaise D., et al. Busulphan plus cyclophosphamide compared with total body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long term follow up of 4 randomized studies. Blood. 98:2001;3569-3574.
85. Clift R.A., Thomas E.D., Fefer A., et al. Treatment of chronic granulocytic leukemia in chronic phase by allogeneic bone marrow transplantation. Lancet. 2:1982;621-624.
86. UCLA Bone Marrow Transplant Team. Bone marrow transplantation in leukemia. Lancet. 2:1997;1197-1201.
87. Jagannath S., Dicke K.A., Armitage J.O., et al. High dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 104:1986;163-168.
88. Shea T.C. High-dose chemotherapy in ovarian cancer: The North American experience. Dicke K.A., Keating A. Autologous Marrow and Blood Transplantation. vol VIII:1997;343-351 Carden Jennings, Charlottesville.
89. Borchardt P.E., Quadri S.M., Freedman R.S., Vriesendorp H.M. Intraperitoneal radioimmunotherapy with human monoclonal IgN in nude mice with peritoneal carcinomatosis. Cancer Biotherapy Pharm. 15:2000;53.
90. Vriesendorp H., Quadri S.M., Borchardt P.E. Tumor therapy with radiolabeled antibodies: Optimization of therapy. Biodrug. 4:1998;275-293.
91. Vriesendorp H.M., Quadri S.M. Radiolabeled immunoglobulin therapy in Hodgkin's disease. An update. Cancer BioTherapy Pharm. 15:2000;431-445.
92. Vriesendorp H.M., Quadri S.M. Barriers and opportunities for radiolabeled immunoglobulin therapy: Expert review. Anticancer Drugs. 1:2001;461-478.